This study examines acute low back pain that is non-specific, meaning pain in the lower back area that has no clear identified cause and has been present for five days or less. The treatment being tested is called an erector spinae plane block, which is a procedure where medication is injected near the muscles along the spine to help reduce pain. During this procedure, patients will receive either the active treatment or placebo. The medications used in the study include dexamethasone phosphate and ropivacaine hydrochloride as injections for the nerve block procedure, and sodium chloride solution for the placebo injection. Additional pain medications that may be used during the study include paracetamol given as tablets or through infusion, ketoprofen given as tablets or through infusion, and tramadol hydrochloride as extended-release tablets for additional pain relief if needed.
The purpose of this study is to find out if the erector spinae plane block is effective in helping patients with non-specific low back pain by reducing their pain and allowing them to move around more easily right away. The study will look at whether this treatment can decrease pain by half and improve the ability to walk within thirty minutes after the procedure is performed.
During the study, patients will undergo the procedure and then be followed for six months. Pain levels will be measured at various times, starting from thirty minutes after the procedure and continuing through the follow-up period. The study will track how well patients can move, how much pain medication they need to take, how many steps they can walk each day in the first few days, and how well they sleep during the first three days. Patients will complete questionnaires at different time points to assess their pain, physical function, quality of life, and any side effects from the pain medications. Information will also be collected about medical visits, physical therapy sessions, any return of back pain, and when patients are able to return to work during the six-month follow-up period.
France 
